Last reviewed · How we verify

NCT05693285: BIO-PRETERM

Preterm Birth and Biomarkers for Cardiovascular Disease

Completed Last updated 26 January 2023
What this trial tests

trial testing No intervention in Preterm Birth in 65 participants. Completed in 2 December 2022.

Timeline
14 November 2022
Primary endpoint
2 December 2022
2 December 2022

Quick facts

Lead sponsorUppsala University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment65
Start date14 November 2022
Primary completion2 December 2022
Estimated completion2 December 2022
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Uppsala University

Who can join

Under 60, female only, with Preterm Birth or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preterm birth is associated with maternal increased risk of cardiovascular disease later in life. In an observational case- control study, investigators want to evaluate whether women with preterm birth have increased levels of biomarkers for cardiovascular disease, to reveal potential pathophysiological mechanisms in common.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Biomarkers associated with cardiovascular disease in women with spontaneous preterm birth: A case-control study.
    Cederlöf ET, Lager S, Larsson A, Sundström Poromaa I, et al · · 2024 · cited 3× · PMID 38379394 · DOI 10.1111/aogs.14813

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Preterm Birth

Currently open trials in the same condition.

Other Uppsala University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05693285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing